Literature DB >> 18528638

Recurrent giant chalazia in hyperimmunoglobulin E (Job's) syndrome.

Pierpaolo Patteri1, Alain Serru, Maria Letizia Chessa, Michele Loi, Antonio Pinna.   

Abstract

Hyperimmunoglobulinemia E (Job's) syndrome is a rare autosomal dominant disorder appearing early in life with recurrent skin and pulmonary infections, characterized by markedly increased serum immunoglobulin E (IgE) levels. We describe a 50-year-old man with a 4-year history of recurrent, multiple giant chalazia in all eyelids. Medications and surgical intervention had produced only transient improvement. The patient had also had pulmonary and scalp infection. Laboratory tests disclosed elevated serum IgE (>1,000 IU/ml) and eosinophilia. As a result, based on the patient's history and clinical and laboratory findings, a diagnosis of Job's syndrome was made. Even though rarely, recurrent multiple giant chalazia may occur as an ophthalmic feature of Job's syndrome. Hyperimmunoglobulinemia E syndrome should be suspected in any case of recurrent giant chalazia, regardless of the patient's age. Measurement of serum IgE and eosinophils, along with internal evaluation, is essential to establish a proper diagnosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18528638     DOI: 10.1007/s10792-008-9238-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  9 in total

Review 1.  Hyperimmunoglobulin E syndrome: two cases and a review of the literature.

Authors:  Christine A DeWitt; Amanda B Bishop; Lucinda S Buescher; Stephen P Stone
Journal:  J Am Acad Dermatol       Date:  2006-05       Impact factor: 11.527

2.  Defective interleukin-12/interferon-gamma pathway in patients with hyperimmunoglobulinemia E syndrome.

Authors:  W G Borges; N H Augustine; H R Hill
Journal:  J Pediatr       Date:  2000-02       Impact factor: 4.406

3.  Hyperimmunoglobulin E syndrome.

Authors:  Benjamin E Rosenberg
Journal:  Dermatol Online J       Date:  2004-11-30

4.  Job's Syndrome. Recurrent, "cold", staphylococcal abscesses.

Authors:  S D Davis; J Schaller; R J Wedgwood
Journal:  Lancet       Date:  1966-05-07       Impact factor: 79.321

5.  Candida endophthalmitis in Job syndrome.

Authors:  R S Haslett; A P Moriarty; P Vijayadurai; J N McGalliard; A Chandna
Journal:  Arch Ophthalmol       Date:  1996-05

6.  Giant chalazia in the hyperimmunoglobulinemia E (hyper-IgE) syndrome.

Authors:  N Crama; P M Toolens; J W M van der Meer; J R M Cruysberg
Journal:  Eur J Ophthalmol       Date:  2004 May - Jun 2004       Impact factor: 2.597

7.  Recurrent Staphylococcus aureus chalazia in hyperimmunoglobulinemia E (Job's) syndrome.

Authors:  John J Destafeno; Sylvia R Kodsi; Jonathan D Primack
Journal:  Am J Ophthalmol       Date:  2004-12       Impact factor: 5.258

8.  [Eye involvement in hyperimmunoglobulin E syndrome].

Authors:  A Frohn; E G Weidle; A Seelhorst; K P Steuhl; H J Thiel
Journal:  Klin Monbl Augenheilkd       Date:  1990-11       Impact factor: 0.700

9.  Eye involvement in hyperimmunoglobulinemia E (Job's) syndrome.

Authors:  M Orhan; Y Ozkan; M Irkeç
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2001 Sep-Oct       Impact factor: 1.402

  9 in total
  3 in total

1.  [Hordeolum and chalazion : (Differential) diagnosis and treatment].

Authors:  Christiane Loth; Christina V Miller; Christos Haritoglou; Eli Sa Beth M Messmer
Journal:  Ophthalmologe       Date:  2021-08-11       Impact factor: 1.059

Review 2.  The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiency.

Authors:  Aleksandra Szczawinska-Poplonyk; Zdzislawa Kycler; Barbara Pietrucha; Edyta Heropolitanska-Pliszka; Anna Breborowicz; Karolina Gerreth
Journal:  Orphanet J Rare Dis       Date:  2011-11-15       Impact factor: 4.123

Review 3.  Ocular involvement in primary immunodeficiency diseases.

Authors:  Sima Hosseinverdi; Hassan Hashemi; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2013-11-30       Impact factor: 8.542

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.